Evidence map›Paper›PMID 37763249›Full record

ReviewLife (Basel, Switzerland)2023

Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review.

Irza Wajid, Alexis Vega, Katherine Thornhill, Jack Jenkins, Chandler Merriman, Debbie Chandler, Sahar Shekoohi, Elyse M Cornett, Alan D Kaye

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Mechanisms of neurodevelopmental toxicity of topiramate.Critical reviews in toxicology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Irza WajidSchool of Medicine, Louisiana State University Health Sciences Center at New Orleans, New Orleans, LA 70112, USA.
Alexis VegaSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Katherine ThornhillSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Jack JenkinsSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Chandler MerrimanSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Debbie ChandlerDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0009-0007-4545-4523
Elyse M CornettDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0001-7961-3931
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-2464-0187
Louisiana State University Health Sciences Center Shreveport · USLouisiana State University Health Sciences Center New Orleans · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity has emerged as a widespread disease with epidemic proportions, necessitating effective management to enhance the overall health outcomes of patients. Medical intervention for weight loss becomes necessary when diet and exercise prove ineffective, and topiramate emerges as a potential treatment option for this global problem. Currently approved as an anti-epileptic and migraine prophylaxis medication, topiramate is frequently utilized as adjunctive therapy for patients with mood and eating disorders, as well as for alcohol use disorders. Its multifaceted mechanisms of action contribute to reducing neuronal excitation and enhancing neuronal inhibition. Given its variety of mechanisms, topiramate shows several off-label outcomes, including weight loss, for patients prescribed this medication. Although the specific mechanism of action concerning weight loss remains uncertain, various hypotheses have been reported. Notably, topiramate may contribute to weight loss by reducing calorie intake, decreasing fat gain, and lowering triglyceride and cholesterol levels. Additionally, its impact on reward pathways associated with food could play a role. Multiple clinical studies have supported the use of topiramate as a weight-loss medication. Notably, the medication demonstrates effectiveness in reducing body weight across different dosages and sustaining weight loss over time, outperforming alternative weight loss methods. Moreover, it was generally well-tolerated in clinical studies, with few side effects observed. In conclusion, topiramate offers promising potential as a weight loss solution and can be a valuable addition to the range of treatment options for combating obesity.

Indexed as

anti-epilepticdecreased neuronal excitationessential tremorsmigrainetopiramateweight loss

Identifiers

PMID37763249
PMCPMC10532729
OpenAlexW4386308158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.